Day 1 - May 10

08:30-10:15  REGISTRATION AND WELCOME COFFEE  
   Sign-in and badge pickup

10:15-10:30  WELCOME ADDRESS  
   Özlem Türeci, CIMT, Mainz, Germany

10:30-12:00  PLENARY SESSION 1  IMPROVING IMMUNITY  
   Chairs: Hansjörg Schild (University Medical Center Mainz, Mainz, Germany), Carl Figdor (Radboud University Medical Center, Nijmegen, The Netherlands)

10:30-11:00  Megan Burger, Koch Institute at MIT, Cambridge, USA  
   "Antigen dominance hierarchies shape anti-tumor T-cell phenotypes and immunotherapy response"

11:00-11:30  Alena Gros Vidal, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain  
   "Refining the identification of personalized tumor-reactive lymphocytes"

11:30-12:00  Jolanda de Vries, Radboud University Medical Center, Nijmegen, Netherlands  
   "Immune-modulation in cancer patients"

12:00-14:00  LUNCH

12:30-13:30  CORPORATE SUPPORTED SYMPOSIUM  
   "Translating science into care in immuno-oncology"  
   Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany) supported by Bristol-Myers Squibb

   Halvard Böning, Goethe University, Frankfurt, Germany  
   "CAR"

   Peter Schirmacher, Heidelberg University Hospital, Heidelberg, Germany  
   "Advancing personalized immuno-oncology therapy"

   Peter Brossart, University Hospital Bonn, Bonn, Germany  
   "Evolving the clinical treatment landscape in Immuno-Oncology"

Joint discussion
14:00-15:30  PLENARY SESSION 2  TUMOR MICROENVIRONMENT
Chairs: Michael Platten (University Hospital Mannheim, Mannheim, Germany), Vincenzo Bronte (University of Verona, Verona, Italy)

14:00-14:30  Michele de Palma, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne "Tumor agnostic dendritic cell vaccines"

14:30-15:00  Robbie Majzner, Stanford University School of Medicine, Palo Alto "Immunotherapy platforms for solid tumors"

15:00-15:30  Dmitry Gabrilovich, AstraZeneca, Gaithersburg, MD "Targeting of myeloid derived suppressor cells in cancer, lessons learned from preclinical studies"

15:30-18:00  COFFEE BREAK

15:30-18:00  POSTER SESSION I  TBA

18:00-19:00  KEYNOTE LECTURE
Chair: tba
Douglas Hanahan, Ludwig Institute for Cancer Research Lausanne, Switzerland "Hallmarks of cancer: the immune dichotomy"

Day 2 - May 11

08:30-10:00  PLENARY SESSION 3  NOVEL TARGETS
Chairs: Harpreet Singh (Immatics, Tübingen, Germany), Sebastian Kreiter (TRON, Mainz, Germany)

08:30-09:00  Mads Hald Andersen, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Copenhagen/Herlev, Denmark "Immune modulatory vaccines in cancer therapy"

09:00-09:30  Kellie Smith, Johns Hopkins Medicine, Baltimore, USA "Discovering mechanisms of response and resistance to checkpoint blockade using integrated immunogenomics"

09:30-10:00  Andrew Sewell, Cardiff University, Cardiff, UK "New modes of T-cell recognition and novel broadly-expressed T-cell epitopes by dissection of cancer immunotherapy success"
2022 CIMT Annual Meeting
Program Schedule*
*Sessions and times are still subject to change.
Program marked in magenta are available both on-site and on livestream

10:00-10:30  COFFEE BREAK

10:30-12:00  PLENARY SESSION 4  IMMUNOMETABOLISM
Chairs: Ignacio Melero (University of Navarra, Pamplona, Spain), Sjoerd van der Burg (Leiden University Medical Center, Leiden, The Netherlands)

10:30-11:00  Martina Seiffert, German Cancer Research Center (DKFZ), Heidelberg, Germany
"A novel role of IL-10 in maintaining anti-tumor immunity"

11:00-11:30  Shiladitya Sengupta, Brigham and Women's Hospital, Cambridge, MA
"Beyond the classical T cell immune checkpoint inhibitors"

11:30-12:00  Lydia Dyck, Max Delbrück Center for Molecular Medicine, Berlin, Germany
"Obesity suppresses anti-tumor immunity"

12:00-14:00  LUNCH

14:00-15:30  PLENARY SESSION 5  NOVEL IMMUNOANALYTICS
Chairs: Niels Halama (NCT, Heidelberg, Germany), Sine Reker Hadrup (Technical University Denmark, Copenhagen, Denmark)

14:00-14:30  Ali Ertürk, Helmholtz Zentrum München, Munich, Germany
"AI-based imaging and molecular methods for personalized medicine"

14:30-15:00  Daniela Thommen, Netherlands Cancer Institute, Amsterdam, The Netherlands
"Dissecting and modulating reactive anti-tumor immunity in patient-derived tumor fragments"

15:00-15:30  Daniel Schraivogel, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
"High-speed fluorescence image-enabled cell sorting"

15:30-18:00  COFFEE BREAK

15:30-17:30  POSTER SESSION II  TBD
2022 CIMT Annual Meeting
Program Schedule*
*Sessions and times are still subject to change.
Program marked in magenta are available both on-site and on livestream

17:30-18:00  COMPANY SEMINAR
supported by Miltenyi Biotec
Sophia Lollies, Miltenyi Biotec, Bergisch Gladbach, Germany
"From gene-editing manufacturing to analytics: the complete clinical T cell workflow"

19:30-23:00  SOCIAL EVENT
Free entry for all on-site conference participants.

Day 3 - May 12

08:30-10:00  SHORT TALK SESSION I  THERAPEUTIC VACCINATION
Chairs: Jolanda de Vries (Radboud University Medical Center, Nijmegen, The Netherlands), Kris Thielemans (Vrije Universiteit, Brussels, Belgium)

08:30-08:45  Matthias Eyrich, University Medical Center Würzburg, Würzburg, Germany
"Interim analysis of the HIT-HGG Rez Immunvac study -dendritic cell vaccination with partial Treg depletion and double checkpoint blockade in children with relapsed high-grade gliomas"

08:45-09:00  Katka Franke, Frame Therapeutics, Amsterdam, The Netherlands
"Development of whole Framome personalized cancer vaccines"

09:00-09:15  Hajer Fritah Guiren, Ludwig Institute for Cancer Research, University of Lausanne, Switzerland
"Personalized cancer vaccination strategies: whole tumor-based vaccines versus neoepitope-based vaccines"

09:15-09:30  Dario Francesco Marzella, Radboud University Medical Center, Nijmegen, The Netherlands
“PANDORA: a fast, anchor-restrained 3D-modelling protocol for peptide-MHC complexes”

09:30-09:45  Armin Rabsteyn, University Children's Hospital Tübingen, Tübingen, Germany
"IVAC-ALL-1: analysis of a completed phase I/II clinical trial on personalized peptide vaccination based on patient-individual tumor-specific variants in relapsed pediatric acute lymphoblastic leukemia"

09:45-10:00  Jeroen van Bergen, Immunetune, Leiden, The Netherlands
"Personalized synthetic polyepitope DNA cancer vaccines including a novel pyroptotic adjuvant synergize with checkpoint inhibitor therapy to generate effective anti-tumor T cell immunity"
08:30-10:00  SHORT TALK SESSION II CELLULAR THERAPY
Chairs: Michael Nishimura (Loyola University Medical Center, Maywood, USA), Andrew Kaiser (BioNTech, Mainz, Germany)

08:30-08:45  Hideho Okada, University of California, San Francisco, USA
"Novel "prime-and boost" concept of T cell therapy using the synNotch circuit to overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma"

08:45-09:00  Johanna Chiffelle, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
"T cell dynamics in melanoma patients receiving TIL therapy"

09:00-09:15  Bastian Kruse; Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany
"Intratumoral interaction dynamics of CD4+ T cells with myeloid cells during tumor regression"

09:15-09:30  Anne Marie Senz, LMU University Hospital, Munich, Germany
"Pre-conditioning of the TME using RIG-I agonists facilitates CAR T cell infiltration and promotes antigen spreading in pre-clinical models of pancreatic cancer"

09:30-09:45  Sophia Stock, LMU University Hospital, Munich, Germany
"P329G-CAR T cells engineered to recognize the P329G-Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors"

09:45-10:00  Martin Wermke, University Hospital Dresden, Dresden, Germany
"Clinical outcomes of solid cancer patients treated with autologous TCR-T cells targeting PRAME in the ongoing ACTengine® IMA203 phase 1 dose escalation trial"

10:00-10:30  COFFEE BREAK

10:30-12:00  SHORT TALK SESSION III NEW TARGETS, LEADS, AND BIOMARKERS
Chairs: Angelika Riemer, DKFZ, Heidelberg, Germany, Steven O'Day (Agenus, Lexington, USA)

10:30-10:45  Markus Haake, CatalYm GmbH, Planegg-Martinsried, Germany
"Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment"

10:45-11:00  Ayse Nur Menevse, Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany
"Translocator protein 18 kDa (TSPO) acts as an immune resistance gene involved in the T-cell mediated immune control of glioblastoma"
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:15</td>
<td>Stefano Sammichele</td>
<td>Ichnos Sciences, Epalinges, Switzerland</td>
<td>&quot;ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38 positive hematologic malignancies&quot;</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Celina Tretter</td>
<td>German Cancer Consortium of Translational Cancer Research (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany</td>
<td>&quot;Integrated multi-variate genomic, immunopeptidomic and functional analyses reveal RNA as a superior source for entity-agnostic neoantigen identification correlating with T-cell infiltration in the tumor&quot;</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>Sandra Wagner</td>
<td>University Medicine Rostock, Rostock, Germany</td>
<td>&quot;Increased tumor cell recognition of colorectal cancer patients’ peripheral and tumor-infiltrating T cells stimulated by neoantigenic and cryptic peptides&quot;</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>David Weber</td>
<td>TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz Mainz, Germany</td>
<td>&quot;Accurate detection of tumor-specific gene fusions with EasyFuse reveals strongly immunogenic personal neo-antigens&quot;</td>
</tr>
</tbody>
</table>

10:30-12:00 SHORT TALK SESSION IV  TUMOR BIOLOGY & INTERACTION WITH THE IMMUNE SYSTEM

Chairs: Mustafa Diken (TRON, Mainz, Germany), Tobias Bopp (University Medical Center, Mainz, Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:45</td>
<td>Martina Anselmi</td>
<td>University of Milan, Milan, Italy</td>
<td>&quot;Dissecting the cross-talk between melanoma stem cells and neutrophils&quot;</td>
</tr>
<tr>
<td>10:45-11:00</td>
<td>Florian Bieberich</td>
<td>ETH Zurich, Zurich, Switzerland</td>
<td>&quot;TCR-QR: Identifying tumour-reactive TCRs for personalized T cell therapies&quot;</td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>Michael Delacher</td>
<td>University Medical Center of the Johannes Gutenberg-University Mainz Mainz, Germany</td>
<td>&quot;Tissue repair in the tumor microenvironment&quot;</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Ella Preugszat</td>
<td>University Hospital Cologne, Cologne, Germany</td>
<td>&quot;Cancer-specific differences of tertiary lymphoid structures and cellular responses against frequently expressed cancer testis antigens&quot;</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>Saskia J. Santegoets</td>
<td>Leiden University Medical Center, Leiden, The Netherlands</td>
<td>&quot;Long surviving vulvar cancer patients with active intratumoral immune infiltration and signaling are potential candidates for neoadjuvant checkpoint therapy&quot;</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>Meggy Suarez-Carmona</td>
<td>German Cancer Research Center (DKFZ), Heidelberg, Germany</td>
<td>&quot;Visceral adipose tissue proximity as a biomarker of response to immunotherapy in epithelial ovarian cancer: insights from patient-derived tissue explants&quot;</td>
</tr>
</tbody>
</table>
2022 CIMT Annual Meeting
Program Schedule*
*Sessions and times are still subject to change.
Program marked in magenta are available both on-site and on livestream

12:00-13:00 SHORT TALK SESSION V IMPROVING IMMUNITY
Chairs: Steve Pascolo (University Hospital of Zurich, Zurich, Switzerland), Megan Burger (Koch Institute at MIT, Cambridge, USA)

12:00-12:15 Assunta Cirella, Universidad de Navarra Pamplona, Spain
"Synergistic effects of Intratumoral mRNA transfer of single chain interleukin 12 and a decoy-resistant variant of interleukin 18"

12:15-12:30 Stefan Eichmüller, German Cancer Research Center (DKFZ), Heidelberg, Germany
"Radioimmunotherapy with carbon ions and CTLA4-blockade improves growth control of local and distant tumors in a preclinical mouse model"

12:30-12:45 Shaun Maguire, University of Southampton, Southampton, UK
"Investigating the therapeutic potential of monoclonal antibodies targeting human GITR"

12:45-13:00 Jim Middelburg, Leiden University Medical Center, Leiden, The Netherlands
"CD3-bispecific antibody therapy is effective in solid tumors after increased T cell infiltration induced by vaccines"

12:00-13:00 SHORT TALK SESSION VI IMMUNOMONITORING
Chairs: Cécile Gouttefangeas (University of Tübingen, Tübingen, Germany), Isabel Poschke (DKFZ, Heidelberg, Germany)

12:00-12:15 Simone Blaess, University of Tuebingen / Werner Siemens Imaging Center, Tübingen, Germany
"In vivo T cell activation kinetics visualized by longitudinal OX40- and CD69-immunoPET during combination cancer immunotherapy"

12:15-12:30 Kirsty McBain, Sartorius (Essen BioScience), Royston, United Kingdom
"Quantify T cell response in 3D tumor spheroids using advanced flow cytometry and live-cell analysis"

12:30-12:45 Jan Musil, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
"Identification of AML relapse associated immune signatures in highly immunocompromised post-HSCT patients"

12:45-13:00 Anna Schöllhorn, University of Tübingen, Tübingen, Germany
"Staining of activated β2-integrins combined with extracellular activation markers for sensitive assessment of antigen-specific CD4+ and CD8+ T cells by flow-cytometry"

13:00-15:00 LUNCH
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Presenter(s)</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:50</td>
<td>SPECIAL SESSION  CHEMICAL IMMUNOLOGY</td>
<td>Chair: Stephan Grabbe (University Medical Center Mainz, Mainz, Germany) supported by: SFB1066</td>
<td></td>
</tr>
<tr>
<td>13:50-14:10</td>
<td>Dan Peer, Tel Aviv University, Tel Aviv, Israel</td>
<td>&quot;RNA therapeutics is going beyond the liver&quot;</td>
<td></td>
</tr>
<tr>
<td>14:10-14:30</td>
<td>Helena Florindo, University of Lisbon, Lisbon, Portugal</td>
<td>&quot;Regulation of solid tumors immunity using nanotechnology&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Toszka Bohn, University Medical Center Mainz, Mainz, Germany</td>
<td>&quot;Modulation of acidosis dependent immune cell polarization in the tumor microenvironment&quot;</td>
<td></td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>POSTER AWARDS</td>
<td>TBA</td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>PLENARY SESSION 6  CELLULAR THERAPY</td>
<td>Chairs: Johanna Olweus (Oslo University Hospital, Oslo, Norway), Mathias Theobald (University Medical Center Mainz, Mainz, Germany)</td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Andreas Mackensen, University Hospital Erlangen, Erlangen, Germany</td>
<td>&quot;A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T and CARVac-based in vivo expansion to improve treatment of patients with CLDN6+ advanced solid tumors&quot;</td>
<td></td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Luca Gattinoni, Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany</td>
<td>&quot;CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies&quot;</td>
<td></td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Chiara Bonini, IRCCS Ospedale San Raffaele, Milan, Italy</td>
<td>&quot;Genome editing for cancer immunotherapy&quot;</td>
<td></td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>CONFERENCE CLOSING</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>